Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

• Egile Nagusiak: Nakamura T (Egilea), Kubota T (Egilea), Iwakaji A (Egilea), Imada M (Egilea), Kapás M (Egilea), Morio Y (Egilea)
• Formatua: Liburua
• Argitaratua: Dove Medical Press, 2016-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Tadakatsu Nakamura,1 Tomoko Kubota,1 Atsushi Iwakaji,1 Masayoshi Imada,1 Margit Kapás,2 Yasunori Morio1 1Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan; 2Developmental Drug Metabolism and Pharmacokinetics, Gedeon Richter Plc, Budapest, Hungary Purpose: Cari...